Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study

Author:

Nguyen Thi Thu Ha1ORCID,Fournier Agnès1ORCID,Courtois Émeline2ORCID,Artaud Fanny1ORCID,Escolano Sylvie2ORCID,Tubert‐Bitter Pascale2ORCID,Boutron‐Ruault Marie‐Christine1ORCID,Degaey Isabelle1,Roze Emmanuel34ORCID,Canonico Marianne1ORCID,Ahmed Ismaïl2ORCID,Thiébaut Anne C.M.2ORCID,Elbaz Alexis1ORCID

Affiliation:

1. Université Paris‐Saclay, UVSQ, Univ. Paris‐Sud, INSERM U1018, Team «Exposome, Heredity, Cancer and Health», CESP Villejuif France

2. Université Paris‐Saclay, UVSQ, Univ. Paris‐Sud, INSERM U1018, Team «High‐Dimensional Biostatistics for Drug Safety and Genomics», CESP Villejuif France

3. Sorbonne Université, AP‐HP, Département de Neurologie, Hôpital Pitié‐Salpêtrière Paris France

4. INSERM U1127, CNRS 7225, Team «Normal and Abnormal Motor Control: Movement Disorders and Experimental Therapeutics», Institut du Cerveau Paris France

Abstract

AbstractBackgroundStatins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time‐varying exposures.ObjectivesWe examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation.MethodWe used data from the E3N cohort study of French women (follow‐up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case‐control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time‐varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation.ResultsThe case‐control study (693 cases, 13,784 controls) showed differences in case‐control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was significantly associated with lower PD incidence (HR = 0.70, 95% CI = 0.51–0.98), with a dose–response relation for the mean daily dose (P‐linear trend = 0.02). There was no association for hydrophilic statins.ConclusionUse of lipophilic statins at least 5 years earlier was associated with reduced PD incidence in women, with a dose–response relation for the mean daily dose. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Funder

Michael J. Fox Foundation

Publisher

Wiley

Subject

Neurology (clinical),Neurology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3